Barclays Reaffirms Their Hold Rating on Biogen (BIIB)

In a report released today, Emily Field from Barclays maintained a Hold rating on Biogen, with a price target of $185.00.

Claim 30% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Field is a 3-star analyst with an average return of 1.4% and a 42.94% success rate. Field covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Cytokinetics.

In addition to Barclays, Biogen also received a Hold from Bank of America Securities’s Jason Zemansky in a report issued on April 16. However, yesterday, Wells Fargo upgraded Biogen (NASDAQ: BIIB) to a Buy.

Based on Biogen’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.28 billion and a GAAP net loss of $48.41 million. In comparison, last year the company earned a revenue of $2.45 billion and had a net profit of $266.7 million

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BIIB in relation to earlier this year. Most recently, in February 2026, Priya Singhal, the Head of Development of BIIB sold 2,660.00 shares for a total of $531,547.80.